Halozyme Therapeutics (HALO) Tops Q3 EPS by 42c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. FIX
9. TSCO
10. BE

Go back to Halozyme Therapeutics (HALO) Tops Q3 EPS by 42c

HALOZYME REPORTS THIRD QUARTER 2022 FINANCIAL AND OPERATING RESULTS

November 8, 2022 4:01 PM EST

Third Quarter Revenue Increased 80% YOY to $209 Million, with GAAP Diluted Earnings per Share of $0.44 and Non-GAAP Diluted Earnings per Share of $0.741

Record Third Quarter Royalty Revenue Increased 70% YOY to $99.6 Million

Reiterating 2022 Revenue Guidance of $655 Million to $685 Million, Representing 48%-55% Growth over Reported 2021 Revenue     

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today reported its financial and operating results for the third quarter ended September 30, 2022 and... More